Compare Stocks: ZVRA, HRMY, BHC, and PBH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.05 +0.1%	$6.20	$4.33 ▼ $8.00	$2.26B	0.37	2.04 million shs	1.03 million shs
HRMY Harmony Biosciences	$40.28 +1.7%	$40.07	$25.52 ▼ $43.49	$2.31B	1.01	1.03 million shs	487,113 shs
PBH Prestige Consumer Healthcare	$48.20 +0.7%	$49.59	$42.62 ▼ $71.07	$2.27B	0.34	657,261 shs	323,705 shs
ZVRA Zevra Therapeutics	$11.39 +3.5%	$11.52	$8.01 ▼ $15.03	$653.22M	0.98	975,006 shs	730,721 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	+4.13%	-1.63%	+26.60%	-4.95%
HRMY Harmony Biosciences	+1.72%	+1.61%	-3.22%	+9.34%	+51.66%
PBH Prestige Consumer Healthcare	+0.69%	+6.28%	-0.84%	-1.48%	-23.89%
ZVRA Zevra Therapeutics	+3.55%	+14.01%	-5.40%	-14.68%	+7.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.05 +0.1%	$6.20	$4.33 ▼ $8.00	$2.26B	0.37	2.04 million shs	1.03 million shs
HRMY Harmony Biosciences	$40.28 +1.7%	$40.07	$25.52 ▼ $43.49	$2.31B	1.01	1.03 million shs	487,113 shs
PBH Prestige Consumer Healthcare	$48.20 +0.7%	$49.59	$42.62 ▼ $71.07	$2.27B	0.34	657,261 shs	323,705 shs
ZVRA Zevra Therapeutics	$11.39 +3.5%	$11.52	$8.01 ▼ $15.03	$653.22M	0.98	975,006 shs	730,721 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	+4.13%	-1.63%	+26.60%	-4.95%
HRMY Harmony Biosciences	+1.72%	+1.61%	-3.22%	+9.34%	+51.66%
PBH Prestige Consumer Healthcare	+0.69%	+6.28%	-0.84%	-1.48%	-23.89%
ZVRA Zevra Therapeutics	+3.55%	+14.01%	-5.40%	-14.68%	+7.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.14	Hold	$8.00	32.34% Upside
HRMY Harmony Biosciences	2.36	Hold	$47.44	17.79% Upside
PBH Prestige Consumer Healthcare	2.40	Hold	$67.67	40.40% Upside
ZVRA Zevra Therapeutics	3.00	Buy	$27.14	138.30% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, HRMY, BHC, and PBH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$9.00
10/1/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$42.00
9/30/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/24/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/23/2026	ZVRA Zevra Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	PBH Prestige Consumer Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
9/21/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/26/2026	HRMY Harmony Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
8/20/2026	ZVRA Zevra Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$10.27B	0.22	$7.28 per share	0.83	$1.02 per share	5.93
HRMY Harmony Biosciences	$868.45M	2.70	$3.24 per share	12.45	$15.11 per share	2.67
PBH Prestige Consumer Healthcare	$1.10B	2.07	$5.24 per share	9.19	$39.89 per share	1.21
ZVRA Zevra Therapeutics	$106.47M	6.35	$0.98 per share	11.63	$2.75 per share	4.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.50	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
HRMY Harmony Biosciences	$158.69M	$3.08	13.08	9.92	0.31	18.88%	20.06%	14.15%	11/3/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	13.50	9.47	1.50	15.57%	11.39%	5.66%	11/5/2026 (Estimated)
ZVRA Zevra Therapeutics	$83.23M	$0.92	12.38	13.56	N/A	42.82%	54.54%	34.15%	11/4/2026 (Estimated)

Latest ZVRA, HRMY, BHC, and PBH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q2 2027	PBH Prestige Consumer Healthcare	$1.07	N/A	N/A	N/A	$329.15 million	N/A
11/4/2026	Q3 2026	ZVRA Zevra Therapeutics	$0.14	N/A	N/A	N/A	$37.08 million	N/A
11/3/2026	Q3 2026	HRMY Harmony Biosciences	$1.11	N/A	N/A	N/A	$274.55 million	N/A
10/28/2026	Q3 2026	BHC Bausch Health Cos	$1.25	N/A	N/A	N/A	$2.72 billion	N/A
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/5/2026	Q2 2026	ZVRA Zevra Therapeutics	$0.11	$0.25	+$0.14	$0.14	$33.88 million	$39.66 million
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	N/A	1.44	1.08
HRMY Harmony Biosciences	0.13	3.48	3.45
PBH Prestige Consumer Healthcare	1.06	3.23	1.99
ZVRA Zevra Therapeutics	N/A	5.17	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
HRMY Harmony Biosciences	86.23%
PBH Prestige Consumer Healthcare	99.95%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	20.67%
HRMY Harmony Biosciences	11.00%
PBH Prestige Consumer Healthcare	1.50%
ZVRA Zevra Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,300	374.38 million	297.00 million	Optionable
HRMY Harmony Biosciences	293	58.24 million	51.83 million	Optionable
PBH Prestige Consumer Healthcare	890	47.38 million	46.66 million	Optionable
ZVRA Zevra Therapeutics	61	59.38 million	57.19 million	Optionable

ZVRA, HRMY, BHC, and PBH Headlines

Recent News About These Companies

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Rated "Buy" by Wall Street Brokerages

October 8 at 2:15 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Has Consensus Price Target of $27.14

October 8 at 2:13 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Jumps 4.6% - Here's Why

October 7 at 1:39 PM | marketbeat.com

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor

October 6, 2026 | seekingalpha.com

Reviewing Vireo Growth (OTCMKTS:VREOD) & Zevra Therapeutics (NASDAQ:ZVRA)

September 30, 2026 | americanbankingnews.com

Stock Traders Buy High Volume of Put Options on Zevra Therapeutics (NASDAQ:ZVRA)

September 24, 2026 | marketbeat.com

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

September 13, 2026 | marketbeat.com

Zevra Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium

August 25, 2026 | quiverquant.comQ

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

August 25, 2026 | globenewswire.com

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

August 23, 2026 | theglobeandmail.com

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 13, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 11, 2026 | globenewswire.com

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

August 7, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 6, 2026 | prnewswire.com

Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041

August 6, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

August 5, 2026 | zacks.com

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

August 5, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, HRMY, BHC, and PBH Company Descriptions

Bausch Health Cos NYSE:BHC

$6.04 +0.01 (+0.08%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$6.07 +0.03 (+0.48%)

As of 10/9/2026 07:54 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Harmony Biosciences NASDAQ:HRMY

$40.28 +0.68 (+1.72%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$40.16 -0.12 (-0.31%)

As of 10/9/2026 07:30 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Prestige Consumer Healthcare NYSE:PBH

$48.20 +0.33 (+0.68%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$48.23 +0.03 (+0.07%)

As of 10/9/2026 07:30 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Zevra Therapeutics NASDAQ:ZVRA

$11.39 +0.39 (+3.55%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.32 -0.07 (-0.57%)

As of 10/9/2026 07:59 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZVRA, HRMY, BHC, and PBH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZVRA, HRMY, BHC, and PBH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZVRA, HRMY, BHC, and PBH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, HRMY, BHC, and PBH Company Descriptions

Bausch Health Cos NYSE:BHC

Harmony Biosciences NASDAQ:HRMY

Prestige Consumer Healthcare NYSE:PBH

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZVRA, HRMY, BHC, and PBH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZVRA, HRMY, BHC, and PBH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZVRA, HRMY, BHC, and PBH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, HRMY, BHC, and PBH Company Descriptions

Bausch Health Cos NYSE:BHC

Harmony Biosciences NASDAQ:HRMY

Prestige Consumer Healthcare NYSE:PBH

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools